EMA Authorised: Edistride (dapagliflozin propanediol monohydrate) — AstraZeneca AB

View source ↗

Summary

Edistride, containing dapagliflozin propanediol monohydrate, has been authorised for treatment in type 2 diabetes, systolic heart failure, heart failure, and ch…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Heart Failure Systolic
• Type 2 Diabetes Mellitus

Drugs mentioned

• Edistride (dapagliflozin propanediol monohydrate)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2;Heart Failure, Systolic;Heart Failure;Renal Insufficiency, Chronic. MAH: AstraZeneca AB. Decision date: 12/03/2026